NCT00401895

Brief Summary

Coated stents with different diameters are presently commercially available, but clinical studies on the assessment of the best stent diameter for a better clinical efficacy, a reduced number of complications, and an effective portal pressure reduction (essential in the treatment of those pathologies in which TIPS is indicated) still do not exist. Aim of the study The purpose of our study is to compare the clinical efficacy and the incidence of complications of TIPS created with 8- and 10-mm covered stents in patients with hepatic cirrhosis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2006

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

November 17, 2006

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 22, 2006

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2008

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

January 9, 2009

Status Verified

January 1, 2009

Enrollment Period

2.8 years

First QC Date

November 17, 2006

Last Update Submit

January 8, 2009

Conditions

Keywords

TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTCovered stentsportal hypertensionhepatic encephalopathy

Outcome Measures

Primary Outcomes (1)

  • hepatic encephalopathy incidence:

    1 year

Secondary Outcomes (6)

  • incidence of persistent hepatic encephalopathy: defined as the presence of a continuous mental state alteration, with episodes of further worsening episodes;

    one year

  • incidence of recurrent hepatic encephalopathy: defined as the onset of at least three episodes of open hepatic encephalopathy in a six-month period;

    one year

  • incidence of variceal rebleeding: defined as the finding, at esophagogastroduodenoscopy, of ongoing or recent variceal hemorrhage or the finding of blood in the stomach and the presence of varices as the only potential cause of bleeding;

    one year

  • shunt dysfunction: defined as the finding of a portosystemic gradient higher than 12 mm Hg and angiographic evidence of shunt stenosis or occlusion;

    one year

  • recurrence of ascites: defined as the need of performing at least one evacuation of ascitic fluid with paracentesis;

    one year

  • +1 more secondary outcomes

Study Arms (2)

1

ACTIVE COMPARATOR

patients treated with 10 mm stent

Device: TIPS created with 8 or 10 mm covered stent

2

ACTIVE COMPARATOR

patients treated with 8 mm stent

Device: TIPS created with 8 or 10 mm covered stent

Interventions

creation of a shunt between hepatic vein and portal vein with PTFE-covered stents

Also known as: Viatorr Goretex
12

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All consecutive cirrhotic patients who have undergone TIPS at our Department for bleeding of esophagogastric varices refractory to medical or endoscopic treatment or for ascites/hydrothorax refractory to diuretic therapy will be considered eligible for the study.

You may not qualify if:

  • an age \>75 years; past or present history of hepatic encephalopathy;
  • a Z-score at trial making test-A (TMT-A) \>1.5;
  • bilirubine levels \>5 mg/dl;
  • creatinine levels \>3 mg/dl;
  • serious cardiac or pulmonary dysfunction;
  • a Child-Pugh's score \>11;
  • a model end-stage liver disease (MELD) score \>18;
  • portal thrombosis;
  • a diagnosis of hepatic carcinoma;
  • sepsis;
  • spontaneous bacterial peritonitis;
  • renal insufficiency.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gastroenterology Unit. dip. Medicina Clinica Policlinico Umberto I

Roma, 00100, Italy

Location

MeSH Terms

Conditions

FibrosisHypertension, PortalHepatic Encephalopathy

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsLiver DiseasesDigestive System DiseasesLiver FailureHepatic InsufficiencyBrain Diseases, MetabolicBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Oliviero Riggio, MD

    Gastroenterology Unit

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 17, 2006

First Posted

November 22, 2006

Study Start

January 1, 2006

Primary Completion

October 1, 2008

Study Completion

December 1, 2008

Last Updated

January 9, 2009

Record last verified: 2009-01

Locations